Pathology and molecular pathogenesis of renal cell carcinoma

被引:1
作者
Corti, Barbara
Zucchini, Nicola
Fabbrizio, Benedetta
Martorana, Giuseppe
Schiavina, Riccardo
Grigioni, Antonia D'Errico
Grigioni, Walter Franco
机构
[1] Policlin St Orsola, Ist F Affarii, I-40138 Bologna, Italy
[2] Univ Bologna, Dept Urol, Bologna, Italy
[3] Univ Bologna, Div Pathol, F Addarii Inst Oncol, Dept Haematol & Oncol,S Orsola Malpighi Hosp, Bologna, Italy
关键词
grade; molecular pathogenesis; pathology; prognosis; renal cell carcinoma; stage;
D O I
10.1016/j.eursup.2006.03.005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: in this review, we summarise the World Health Organization (WHO) classification of renal cell carcinomas (RCCs) alongside grading and staging systems. General applications of immunohistochemistry, cytogenetics, and cDNA microarrays were reviewed with their implications in tumour diagnosis, prognosis, and therapy. Results: RCCs are classified according to the 2004 WHO classification, which defines three main histopathologic tumour subtypes with distinct clinical behaviour and underlying genetic defects: conventional (clear cell), papillary, and chromophobe RCC. Histopathologic classification and specific genetic mutations are crucial in distinguishing between familial and nonfamilial tumours. The most common four-tiered Fuhrman nuclear grade system is recommended for all types of RCC. Tumour grade is assigned according to the highest grade present; staging is assigned using the Union Internationale Contre le Cancer/American joint Committee on Cancer 2002 classification. Conclusions: Prognosis of patients with RCCs is most accurately predicted by TNM stage. Within stages, Fuhrman grade has a strong predictive value. Although not considered in nuclear grading, sarcomatoid dedifferentiation is a severely negative event for all RCC subtypes. Histologic subtypes of RCCs are not independent prognostic factors comparable with TNM stage and Fuhrman grade. Histologic coagulative tumour necrosis was an independent prognostic factor of outcome for clear cell and chromophobe RCC. Immunohistochemical panels including RCC marker, CD10, and KIT are now available for differential diagnosis of the distinct RCC subtypes. Genetic studies have improved understanding of subtypes, offering a promising approach for clinical diagnosis, prognosis, and possibly therapy. Urologists should be aware that currently many molecular analyses can be performed on RCCs, and when feasible, fresh samples sent to the pathologist. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:573 / 579
页数:7
相关论文
共 37 条
  • [1] Renal-cell carcinoma
    Cohen, HT
    McGovern, FJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) : 2477 - 2490
  • [2] ELBE JN, 2004, PATHOLOGY GENETICS T, P12
  • [3] ELSON PJ, 1988, CANCER RES, V48, P7310
  • [4] Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort
    Frank, I
    Blute, ML
    Leibovich, BC
    Cheville, JC
    Lohse, CM
    Zincke, H
    [J]. JOURNAL OF UROLOGY, 2005, 173 (06) : 1889 - 1892
  • [5] PROGNOSTIC-SIGNIFICANCE OF MORPHOLOGIC PARAMETERS IN RENAL-CELL CARCINOMA
    FUHRMAN, SA
    LASKY, LC
    LIMAS, C
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1982, 6 (07) : 655 - 663
  • [6] GREENE LF, 2002, AM JOINT COMMITTEE C
  • [7] Gronwald J, 1997, CANCER RES, V57, P481
  • [8] TELOMERIC ASSOCIATIONS AND LOSS OF TELOMERIC DNA REPEATS IN RENAL TUMORS
    HOLZMANN, K
    BLIN, N
    WELTER, C
    ZANG, KD
    SEITZ, G
    HENN, W
    [J]. GENES CHROMOSOMES & CANCER, 1993, 6 (03) : 178 - 181
  • [9] C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas
    Huo, L
    Sugimura, J
    Tretiakova, MS
    Patton, KT
    Gupta, R
    Popov, B
    Laskin, WB
    Yeldandi, A
    Teh, BT
    Yang, XMJ
    [J]. HUMAN PATHOLOGY, 2005, 36 (03) : 262 - 268
  • [10] Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO